Boston Scientific Corp. (NYSE:BSX)

255. Boston Scientific (NYSE: BSX) is bottoming. Target: $6-$7. Now is a good time to buy. I'll be voting on this with my caps points. Sure, it is cheap and it lacks catalysts. At this point, the catalyst is effectively a rhetorical question: "who is going to sell?" Since stock prices are a function of daily supply and demand, I expect that the lack of selling at these prices and the bottoming effect will drive the stock into my price range. Eventually, at prices low enough, investors kind of look around at each other and decide that selling doesn't make sense. At that point, you don't need catalysts for upside because you get a self-fulfilling bottoming prophecy that does it on its own.

http://beta.fool.com/bradford86/2012/01/10/price-market-part-37/

Positive:
- New management
- Finally at 15 year lows insiders start buying
- Debt goes down
- And yes, they still have a pipeline which might come up with new innovations
- Short term oversold

Negative:
- Chart in a clean downtrend channel
- In the long-run health care costs have to go down because they can not be paid for but this might still be some years into the future
- Still not really cheap, but a defensive play which might work in the current environment

Category: MT+

New stent coming Q411/Q112 (one in which 40% proceeds won't be going to Abbott), good pipeline/recent aquisitions, forward looking strategy, slowly but surely driving down debt, still a buyout possiblity (new president/CEO-to-be from JNJ..).

Pricing pressure in core ICD and stents market will way heavily on this stock but BSX is posed to gain share in key CRM due to quality problems at STJ. DOJ investigation will hurt STJ more giving a differential advantage to BSX.

Widespread hearing loss in the younger generations will boost sales of Boston Scientific's hearing aid division

Some guy I met on an elevator likes it.

Debt load

stock has a ST drop because of CEO planning on to retire.

Big money is all in on this one.

doing the right things

Important technology in an area of explosive growth and a huge budget for R&D. Debt could be a problem, but this company makes a huge amount of money and it appears that it could reach all of it's obligations if it came down to it.

bad value today with poor acquisitions

Under-appreciated stock on Wall Street. Strong Defibrillator and stent business.

This one has been beaten down too long. Now transitioning to being a profitable, progressive company. Easily a 10 within 6 months

New line of products in future.

The simple truth is that competitors have superior products. The management can't dig themselves out of the hole their in. Damage form poor acquisitions and law suits have taken their toll. When ever you see a slight rise you had better sell, this is why whenever their is a small increase in performance most people start a sell off.....

One of my biggest disappointments. I originally though this was a broken chart not a broken company it looks like I was wrong. Mid 8's seem reasonable

New stent roll out marks significant campaign to regain market share and lost stature. 50% gain in 6 mos.

This nag has been beat bad, but you losers just hang in there waiting for a turn around until your investments are totally gone. This company has lost all hope and respect.